Washington, D.C. 20549






Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934


For the month of August 2017


Commission File Number 001-38177



Clementia Pharmaceuticals Inc.

(Translation of registrant’s name into English)




4150 St Catherine Street West, Suite 550

Montreal, Quebec, Canada, H3Z 2Y5

(Address of principal executive offices)




Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:


Form 20-F Form 40-F


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):


Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):










Exhibit   99.1     Press Release dated August 21, 2017.














Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


    Clementia Pharmaceuticals Inc.
Date: August 21, 2017       By:   /s/ Michael Singer
        Name:   Michael Singer
        Title:   Chief Financial Officer







Exhibit 99.1

Clementia Announces Closing of Over-Allotment Option in its Initial Public Offering

Montreal, Quebec – August 21, 2017 – Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) (the “Company” or “Clementia”), a clinical stage biopharmaceutical company, today announced that the underwriters of its previously announced initial public offering exercised their option to purchase an additional 1,191,000 common shares from Clementia at the public offering price of $15.00 per share, resulting in additional gross proceeds of approximately $17.9 million. As a result, the total initial public offering size was 9,191,000 common shares, for aggregate gross proceeds to Clementia from the offering, before deducting the underwriting discounts and commissions and offering expenses, of approximately $137.9 million.  The common shares began trading on The NASDAQ Global Select Market on August 2, 2017 under the ticker symbol “CMTA”. The exercise of the over-allotment option closed August 18, 2017.

Morgan Stanley & Co. LLC and Leerink Partners LLC acted as book-running managers for the offering.  Wedbush Securities Inc. and BTIG, LLC acted as co-managers for the offering.

The offering was made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from the offices of Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by email at

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). Copies of the registration statement can be accessed through the SEC’s website at This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Clementia Pharmaceuticals Inc.

Clementia is a clinical stage biopharmaceutical company committed to delivering treatments to people who have none. The company is developing its lead candidate palovarotene, a novel RARγ agonist, to treat Fibrodysplasia Ossificans Progressiva (FOP), Multiple Osteochondromas (MO), and other diseases. For more information, please visit

Investor/Media Contact:

Joseph Walewicz
Clementia Pharmaceuticals Inc.

Source: Clementia Pharmaceuticals, Inc.